CHM — Chimeric Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$14.02m
- AU$13.67m
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.064 | 15.1 | 15.7 | 25.4 | 12.5 |
Operating Profit | -0.064 | -15.1 | -15.7 | -25.4 | -12.5 |
Net Income Before Taxes | -0.064 | -15.1 | -15.7 | -25.4 | -12.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.064 | -15.1 | -15.9 | -25.5 | -12.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.064 | -15.1 | -15.9 | -25.5 | -12.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.064 | -15.1 | -15.9 | -25.5 | -12.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0 | -0.08 | -0.044 | -0.059 | -0.018 |
Dividends per Share |